Beelen, D. W., Trenschel, R., Stelljes, M., Groth, C., Masszi, T., Reményi, P., . . . Markiewicz, M. (2020). Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): A randomised, non-inferiority, phase 3 trial. The lancet. Haematology, 7(1), . https://doi.org/10.1016/S2352-3026(19)30157-7
Chicago-Zitierstil (17. Ausg.)Beelen, Dietrich W., et al. "Treosulfan or Busulfan Plus Fludarabine as Conditioning Treatment Before Allogeneic Haemopoietic Stem Cell Transplantation for Older Patients with Acute Myeloid Leukaemia or Myelodysplastic Syndrome (MC-FludT.14/L): A Randomised, Non-inferiority, Phase 3 Trial." The Lancet. Haematology 7, no. 1 (2020). https://doi.org/10.1016/S2352-3026(19)30157-7.
MLA-Zitierstil (9. Ausg.)Beelen, Dietrich W., et al. "Treosulfan or Busulfan Plus Fludarabine as Conditioning Treatment Before Allogeneic Haemopoietic Stem Cell Transplantation for Older Patients with Acute Myeloid Leukaemia or Myelodysplastic Syndrome (MC-FludT.14/L): A Randomised, Non-inferiority, Phase 3 Trial." The Lancet. Haematology, vol. 7, no. 1, 2020, https://doi.org/10.1016/S2352-3026(19)30157-7.